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UBCE2iLuteinizing hormone receptor (LHR) mRNA binding protein (LRBP), identiﬁed as mevalonate kinase, has been
shown tobe a trans factormediating the post-transcriptional regulation of LHRmRNAexpression in ovaries. LRBP
binds to the coding regionof LHRmRNAand accelerates its degradation.Our previous studies in an in vitro system
showed that LRBP represses the translation of LHR mRNA by forming an untranslatable ribonucleoprotein
(mRNP) complex, further suggesting that the untranslatablemRNP complex is directed to themRNA repression/
decay machinery for subsequent mRNA turnover. In the present studies, we used yeast two-hybrid system to
screen a cDNA library which was constructed from LHR down-regulated ovaries. Two proteins were identiﬁed
interacting with LRBP: ribosomal protein S20 (RP S20) and ubiquitin conjugating enzyme 2i (UBCE2i). Their
interactions with LRBP were conﬁrmed by the mating assay, co-immunoprecipitation analyses and in vitro
sumoylation assays. Furthermore,we show that LRBP is a target formodiﬁcation by SUMO2/3 but not by SUMO1,
at K256 and/or K345. Mutation of both lysine residues is sufﬁcient to abrogate the sumoylation of LRBP. These
ﬁndings suggest that the direct interaction of LRBP with the translation machinery, through RP S20, may be
responsible for the transition of LHRmRNA to an untranslatable complex, and that sumoylation of LRBPmay play
a role in targeting the untranslatable mRNP complex to the mRNA decay machinery in speciﬁc cytoplasmic foci.ealth Grant R37 HD 06656.
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Luteinizing hormone (LH) and human chorionic gonadotropin
(hCG), the placental counterpart of LH, are important glycoprotein
hormones regulating gonadal functions in mammals, and their actions
are mediated by the same receptor designated as LHR, which is
expressed primarily in the testis and ovary [1,2]. LHR belongs to the Gs
protein receptor family, and like many members of the family, LHR
expression can be down-regulated by exposure to a high concentra-
tion of its ligand [3,4]. Our laboratory has shown that LHR expression
in ovarian cells is down-regulated by an endogenous preovulatory LH
surge or by administration of a pharmacological dose of hCG, through
a post-transcriptional mechanism [5]. Using a rodent model system,
we identiﬁed an LHR mRNA binding protein (LRBP) in the down-
regulated rat ovary which binds speciﬁcally to a polypyrimidine-rich
sequence in the coding region of LHR mRNA [6] and accelerates its
degradation [7]. The protein was puriﬁed and identiﬁed as being
mevalonate kinase (MVK) [8].Messenger RNA degradation and mRNA translation, the two
important control mechanisms in regulating eukaryotic gene expres-
sion are often related events [9]. Several reports have shown that
inhibition of translation or aberrant translational termination of some
mRNAs destabilizes the transcripts [10,11]. It is proposed that
untranslating mRNAs assemble into translationally repressed ribonu-
cleoprotein complexes (RNPs), which become associated with the
general repression/decay machinery, at speciﬁc cytoplasmic foci
referred to as P bodies, and the transcripts are then either stored or
degraded [12]. Using an in vitro translation system, we demonstrated
that LRBP inhibits the translation of LHR mRNA by forming a
ribonucleoprotein complex [10], and mutation of the nucleotides in
LHR mRNA at the LRBP binding site fully abrogates the inhibitory
effect of LRBP onmRNA translation [13]. On the basis of these ﬁndings,
we hypothesize that LRBP causes the formation of an untranslatable
mRNP complex, which leads to the rapid decay of LHR mRNA by
recruiting the general repression/decay machinery in P bodies.
To address this possibility, we used LRBP as “bait” in a yeast two-
hybrid screen to identify interacting protein partners in LHR down-
regulated ovaries. We identiﬁed two proteins that interact with LRBP,
ribosomal protein S20 (RP S20) and ubiquitin conjugating enzyme 2i
(UBCE2i). RP S20 is a component of the 40S ribosomal subunit. Based
on the known function of RP S20, our results suggest that its
association with LRBP may impair the translation initiation of
LHR mRNA, disrupt its 5′ cap structure and render it untranslatable.
UBCE2i, a SUMO conjugating enzyme is involved inmulti-sumoylation
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shuttling of mRNP complexes to speciﬁc subcellular sites, and thus
gain access to the repression/decay machinery. In summary, our data
suggest the possibility that the LRBP interacting proteins identiﬁed in
this studymight provide amechanistic basis for the degradation of LHR
mRNA.
2. Materials and methods
2.1. Animals and treatments
All animalswerehousedunder the care of theUniversity ofMichigan
Unit of Laboratory Animal Medicine (UM-ULAM). Experimental proto-
cols used in this study were approved by the University Committee on
theUse and Care of Animals (UCUCA). Pseudopregnancywas induced in
22-day-old Sprague–Dawley female rats by a subcutaneous injection of
50 IU pregnant mare serum gonadotropin (PMSG), followed by a 25 IU
hCG injection 56 h later. The day of hCG injectionwas taken as day 0. On
the ﬁfth day of pseudopregnancy, rats were injected with 50 IU hCG to
induce LH receptor down-regulation, and ovaries were collected 9 h
later [14].
2.2. Yeast two-hybrid screening
The bait plasmid was constructed by cloning the complete coding
region of rat LRBP from pCMV4-LRBP [8] into the pGBKT7 vector,
which expresses proteins in fusion with Gal4 binding domain. Since
the present study focuses on the function of mevalonate kinase as an
RNA binding protein, this protein is referred to as LRBP in the
manuscript. The pseudopregnant rat ovary cDNA library was con-
structed using theMatchmaker Library Construction and Screening Kit
(Clontech, Mountain View, CA). In brief, 2 µg of total RNA was
extracted frompseudopregnant rat ovaries for cDNA synthesis and the
ﬁrst strand cDNAwas ampliﬁed by Long Distance PCR. Puriﬁed cDNAs
were linked to the sequence encoding Gal4 activation domain in
pGADT7 vector, by homologous recombination in yeast strain AH109
[15].
pGBKT7-LRBP bait and pGADT7-cDNA library were co-transformed
into yeast AH109 cells and transformants were plated on synthetic
minimal medium lacking tryptrophan, leucine and histidine but
supplemented with adenine. After 3 days, the growing clones were
restreaked onminimalmediumplates and tested by theβ-galactosidase
ﬁlter assay. Plasmids were isolated from positive clones, using the
Zymoprep II Kit (ZymoResearch, Orange, CA) and theDNA inserts of the
library plasmids were sequenced at the Biomedical Sequencing Core
Facility of the University of Michigan.
2.3. Protein–protein interaction analyses
The complete coding region of each LRBP interacting protein was
ampliﬁed from total RNA by RT-PCR, and cloned in the proper reading
frame into pGADT7 (prey) vectors, provided by the Matchmaker 3
Yeast Two-Hybrid Screening Kit (Clontech). The yeast strain AH109
transformed with a speciﬁc prey construct was mated with the Y187
strain transformed with the bait construct. The progenies were
checked for growth on minimal medium plates without tryptophan,
leucine and histidine, to conﬁrm the interaction between bait and
prey.
The plasmid constructs were then used to synthesize [35S]-
methionine labeled proteins, using the TNT Quick Coupled Transcrip-
tion/Translation System (Promega, Madison, WI). Because of the
location of the T7 promoter in the parent pGBKT7 and pGADT7 vectors,
in vitro translation products do not contain any portion of the Gal4
protein. These productswere examined by 10% SDS-PAGE as described
in detail previously [10]. Any pairwise mixtures of these translationproducts were analyzed for in vitro association, following the
instructions of Matchmaker Co-Immunoprecipitation Kit (Clontech).
2.4. Cell culture and transfection
Human embryonic kidney cells expressing the large T-antigen
(293T) were maintained in Dulbecco's Modiﬁed Eagle's medium
(Sigma, St. Louis, MO) containing 10 mM HEPES, 50 µg/ml gentami-
cin, 2 U/ml nystatin and 10% fetal bovine serum at 37 °C in a
humidiﬁed atmosphere containing 5% CO2. Cells were plated at 40–
50% conﬂuency in 60 mm dishes and transiently transfected with 2 µg
of plasmid DNA at 12 h, using FuGENE 6 (Roche, Indianapolis, IN).
Cells were then collected 48 h post-transfection, for the preparation of
whole cell lysates [16] or S-100 fractions.
2.5. Preparation of cytosolic proteins (S-100 fractions)
Forty-eight hours after transfection, 293T cells were detached
from culture dishes using NaCl/Pi-EDTA. The cell pellets were
homogenized at 4 °C in buffer A (10 mM HEPES, pH7.9; 0.5 mM
MgCl2; 50 µM EDTA; 5 mM dithiothreitol; and 10% glycerol) contain-
ing 50 mM KCl and protease inhibitor mixture [6]. The homogenates
were centrifuged at 105,000×g, 4 °C for 90 min, and the supernatants
(S-100 fractions) were quantiﬁed using the BCA Protein Assay Kit
(Pierce, Rockfond, IL).
2.6. Western blot analysis
Whole cell lysates or S-100 fractions were denatured by boiling for
5 min in the presence of loading buffer and were subjected to SDS-
PAGE. After electrophoresis, the proteins were electroblotted onto
nitrocellulosemembranes (0.2-µmpore) and blockedwith 5%milk for
1 h at room temperature. The membranes were then incubated
overnight with primary antibodies at 4 °C. Anti-LRBP polyclonal
antibody was raised against its ﬁrst 15N-terminal amino acids—
MLSEVLLVSAPGKVI [14]. Anti-myc and anti-HA antibodies were
included in the Matchmaker Co-Immunoprecipitation Kit (Clontech).
Anti-SUMO polyclonal antibodies were included in the Sumoylation
Assay Kit (BioMol, Plymouth, Meeting, PA). The presence of immune
complexes was detected using the SuperSignalWest FemtoMaximum
Sensitivity Substrate (Pierce).
2.7. Site-directed mutagenesis
The mutants of rat LRBP in pCDNA4 vector were prepared using
the QuickChange Site-directed Mutagenesis Kit (Stratagene, La Jolla,
CA) according to the manufacturer's protocol. The mutagenic sense
(S) primers used were as follows: K256R, 5′-GTCAGAAGCAGGCTAAT-
CAGGTTCCCTGAGATCATGGCCCCG-3′; K345R, 5′-GGCATCACCCTCCT-
GAGGCCAGGTCTAGAG-3′. The K256R single mutant was then
employed as template for the synthesis of K256R/K345R double
mutant, with the K345R mutagenic primer. Mutations were veriﬁed
by DNA sequencing.
2.8. In vitro sumoylation analysis
Wild type and mutant constructs of LRBP, over-expressed in 293T
cells, were assayed for sumoylation using the Sumoylation Kit
(BioMol) by following the manufacturer's protocol. Brieﬂy, aliquots
of S-100 fractions were mixed with SUMO activating enzyme E1
(50 nM), SUMO conjugating enzyme E2 (500 nM), SUMO (250 nM)
and Mg2+-ATP (5 mM) in the buffer supplied with the assay kit and
incubated at 30 °C for 60 min. The reaction was quenched by adding
20 µl of SDS-PAGE gel loading buffer and heating at 65 °C for 20 min.
Sumoylated proteins were then separated on 4–15% gradient gel and
detected by western blot.
Fig. 1. Examination of the interaction between LRBP–Gal4 BD (binding domain) and
prey–Gal4 AD (activation domain) by yeast mating assay. (A) A schematic represen-
tation of rat LRBP (fused in frame to the Gal4 BD sequence in plasmid pGBKT7) and prey
proteins (fused in frame to the Gal4 AD sequence in plasmid pGADT7). (B) The
complete coding regions of UBCE2i, eIF5A and RPS20 were cloned and fused in frame to
the Gal4 AD sequence in plasmid pGADT7 and the plasmids were transformed into
AH109 yeast strain. Rat LRBP was fused to the Gal4 BD sequence in plasmid pGBKT7 and
the plasmid was transformed into Y187 yeast strain. Protein–protein interactions were
evaluated bymating transformed AH109 and Y187 yeasts and examining the growth on
SD-WHL plates (lacking tryptophan, leucine and histidine). The presence of both
plasmids in mated yeasts was veriﬁed by growth on SD-WL plates (not shown). LRBP–
LRBP interaction was used as a positive control. Lamin was used as a negative control.
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3.1. Identiﬁcation of proteins that interact with LRBP
We have previously shown that LRBP, binding speciﬁcally to the
coding region of LHR mRNA, leads to the formation of an untrans-
latable mRNP complex. The mRNA component in this complex is
rapidly degraded presumably by being directed to an mRNA decay
pathway in the cytosol [10]. In order to identify LRBP interacting
partners during this process, we employed the yeast two-hybrid
system and screened a cDNA library constructed from hCG down-
regulated rat ovaries.
The entire rat LRBP protein was used as the bait. A total of ∼800,000
transformants were plated and 148 clones grew out on plates with
minimal medium lacking histidine. Sixty-seven of these colonies
showed a strong blue color in the β-galactosidase ﬁlter assay. Library
plasmids were extracted from these positive colonies, multiplied and
sequenced by automated sequencing. UsingGeneRunner Software 3.05,
the DNA sequences obtained were translated into protein sequences,
which were then subjected to BLAST analysis using the NCBI database.
The results revealed that 2 clones contained in-frame cDNA encoding
the sumo-conjugating enzyme UBCE2i (Table 1), 1 clone had the heat
shock 70 kDa protein 5 insert, 1 clone contained the cDNA of eukaryotic
initiation factor 5A (eIF5A), and 1 clone had the cDNA of ribosomal
protein S20. LRBP itself was also screened out, which is consistent with
the previous report that LRBP can exist as a dimer [17]. Table 1
summarizes the identiﬁed protein fragments and functional character-
istics of these proteins. The other sequenced clones either represent
molecules not cloned in frame with Gal4 activation domain (AD) or
proteins of uncharacterized function.
3.2. Veriﬁcation of the interactions between LRBP and prey proteins
Next we performed yeast mating assay and in vitro Co-IP to verify
the observed interactions between LRBP and prey proteins. Table 1
shows that UBCE2i and eIF5A had their entire coding sequence fused
to the Gal4 AD, while HS70p5 and RP S20 had only their C-terminal
regions expressed in the fusion proteins. Using total RNA from rat
ovaries as template, the complete coding region of each prey protein
(Fig. 1A) was reverse transcribed, ampliﬁed and cloned into the
pGADT7 vector. The plasmids were then transformed into AH109
yeast strain (MATa type). In addition, LRBP and lamin sequences
were cloned into pGBKT7 vector and transformed into Y187 yeast
strain (MATα type). AH109 strain mates with Y187 strain and their
progenies inherit plasmids from both AH109 and Y187. Transformed
AH109 and Y187 were mixed and cultured on minimal medium
plates lacking tryptophan, leucine and histidine. Lamin functions as a
negative control, because it has no known interacting protein
partner, while the LRBP–LRBP interaction serves as a strong positive
control. Our results showed that UBCE2i, eIF5a and RP S20, fused to
Gal4 AD, interact with LRBP fused to Gal4 BD, and these proteins do
not interact with lamin (Fig. 1B). However, interaction between
HS70p5 and LRBP was not observed in the mating assay (data not
shown).Table 1
Characteristics of LRBP interacting proteins identiﬁed by the yeast two-hybrid assay.
Protein interacting with LRBP Clone
number
Insert length
(bp)
Corresponding reg
on the protein (aa
UBCE2i (also named Ube2i, UBCE2A) 1, 22 ∼1100 1–158
Heat shock 70 kDa protein 5 (HS70p5) 13 ∼900 404–650
eIF5A 35 ∼1800 1–154
RPS20 53 ∼500 51–119
LRBP 17, 29 ∼1700 1–395The protein–protein interactions were further tested by in vitro
transcription-translation and co-immunoprecipitation. [35S]-labeled
prey proteins (UBCE2i, RP S20 and SV 40 large T) and bait proteins
(LRBP and p53) were synthesized in vitro (Fig. 2A) and these proteins
were immediately co-immunoprecipitated using anti-Myc monoclo-
nal antibody (Fig. 2B and C). Myc-tagged 35S-labeled LRBP reacted
with anti-Myc monoclonal antibody when subjected to immunopre-
cipitation (lane 5 in Fig. 2B and lane 2 in Fig. 2C). [35S]-labeled UBCE2i
or RP S20 was mixed with [35S]-labeled Myc-tagged LRBP and the
mixture was co-immunoprecipitated using anti-Myc monoclonal
antibody (lane 4 in Fig. 2B, and lane 1 in Fig. 2C). No band was
observed when c-Myc immunoprecipitation was done with UBCE2i or
RP S20 in the absence of Myc-tagged LRBP (lane 6 in Fig. 2B and lane 3
in Fig. 2C) indicating that neither UBCE2i nor RP S20 cross-reacted
with anti-Myc antibodies. The p53–SV40 interaction served as a
positive control for the Co-IP assays. Interestingly, it was observedion
)
Function
Protein stabilization, nuclear-cytosolic transport, transcription regulation, etc.
Protein folding and transport in ER
RNA translation
RNA translation
Cholesterol synthesis enzyme, RNA binding protein
Fig. 2. Examination of the interactions between epitope-tagged LRBP and prey proteins in vitro. (A) A list of proteins synthesized with [35S]-methionine in vitro. Proteins expressed in
pGBKT7 plasmids (LRBP and p53) are Myc-tagged. (B) Proteins were in vitro synthesized in the presence of 35S-methionine. Freshly synthesized LRBP and UBCE2i were mixed
together and co-immunoprecipitated with anti-Myc antibody (lane4). The precipitated complex was analyzed by SDS-PAGE and autoradiography. Immunoprecipitation was speciﬁc
(lane5, LRBP only) and no cross reaction was observed (lane6, UBCE2i only). The p53–SV40 interaction was used as a positive control (lanes 1–3). Position of each protein ladder
band was marked on the ﬁlm. (C) Proteins were in vitro synthesized in the presence of 35S-methionine. LRBP and RP S20 were co-immunoprecipitated with anti-Myc antibody
(lane 1) and analyzed by SDS-PAGE and autoradiography. Immunoprecipitation was speciﬁc (lane 2, LRBP only) and no cross reaction was observed (lane 3, RPS20 only). Position of
each protein ladder band was marked on the ﬁlm.
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co-immunoprecipitated by LRBP in vitro (data not shown). One
possible explanation is that the removal of Gal4 activation domain
causes a conformational change in eIF5A and prohibits the eIF5A–
LRBP interaction. Another possibility is that certain co-factors present
in yeast but absent in the in vitro reaction are required for the eIF5A–
LRBP interaction. Taken together, our experiments veriﬁed that
UBCE2i and RP S20 interact with LRBP both in yeast and in vitro.
3.3. Analysis of the interaction between LRBP and UBCE2i
UBCE2i, the human homologue of yeast UBC9, was originally
thought to be a conjugating enzyme for ubiquitination [18], leading to
rapid degradation of its targets [19,20]. Later, the enzyme was shown
to be responsible for sumoylation, which does not cause protein
degradation, but instead regulates subcellular localization of proteins,
transcription factor activity and other cellular processes [21]. Since
previous studies have shown that UBCE2i is able to interact with an
mRNA binding protein AUF1, suggesting a possible role in regulating
mRNA stability [22], we sought to further investigate its role in the
LRBP mediated mRNA decay. The ﬁrst step was to examine whether
UBCE2i is associated with LRBP in mammalian cells.
293T cells were transfected to express Myc-tagged LRBP, with
either HA-tagged UBCE2i or HA-tagged LRBP (lanes 5 and 6 in Fig. 3A).
The cell lysates were prepared 48 h after transfection and were
incubated with protein A agarose beads conjugated with anti-Myc
antibody (lanes 1–6 in Fig. 3B). Immunoprecipitated samples were
examined by western blotting using an anti-HA antibody. The results
showed that LRBP forms a complex with itself (lane 5 in Fig. 3B) and
with UBCE2i (lane 6 in Fig. 3B). Based on the results of co-immunoprecipitation studies described, we conclude that LRBP
interacts with UBCE2i under in vitro conditions.
3.4. LRBP, a novel target of sumoylation
Since UBCE2i predominantly exerts its functions through sumoy-
lation [20], we investigated whether LRBP is capable of SUMO
modiﬁcation. It has been known that most of the SUMO-modiﬁed
proteins contain a SUMO consensus sequence (SUMO-CS) which is
engaged in SUMO attachment. SUMOplot™ Analysis software
(Abgent, San Diego, CA) was designed to predict the sites where
sumoylation most likely occurs [23].
Using the software, we scrutinized the LRBP sequence and two
putative sumoylation sites were identiﬁed (Fig. 4A). Both sites are on
the C-terminal domain of LRBP: α-8 helix and β-13 sheet respectively
(Fig. 4D). These elements are highly conserved. The consensus
sequence scores (CS) are 0.80 (K256) and 0.73 (K345) for human,
and 0.84 (K256) and 0.73 (K345) for rat.
To verify that LRBP is sumoylated at K256 and/or K345, we
constructed plasmids containing mutant LRBP sequences, by substi-
tuting lysine with arginine at position 256 and/or position 345. 293T
cells were transfected to express wild type or mutant forms of LRBP.
S-100 fractions were prepared and quantitated by BCA assay. Analysis
of LRBP expression by western blot using anti-LRBP polyclonal
antibody showed that the mutations had no signiﬁcant inﬂuence on
the expression of LRBP in 293T cells (Fig. 4B). Aliquots of S-100
fractions were then subjected to in vitro sumoylation assay, as
described in the Section 2. The reaction mixtures were examined by
western blot using anti-SUMO2/3 antibody, which recognizes the N-
terminus of SUMO2/3 molecules. Three major bands representing
Fig. 3. Examination of the interactions between LRBP and UBCE2i in 293T cells. (A) 293T
cells were transiently transfected with 1. pCMV-HA and pCMV-Myc; 2. pCMV-HA-LRBP
and pCMV-Myc; 3. pCMV-HA-UBCE2i and pCMV-Myc; 4. pCMY-HA and pCMV-Myc-
LRBP; 5. pCMV-HA-LRBP and pCMV-Myc-LRBP; 6. pCMV-HA-UBCE2i and pCMV-Myc-
LRBP. 20 µg of whole cell lysate from each transfection was subjected to SDS-PAGE and
examined with both Myc and HA antibodies. (B) The lysates were immunoprecipitated
with 10 µl of protein A agarose beads (Myc antibody conjugated) and the samples were
subjected to SDS-PAGE and immunoblotted with HA antibody.
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expressed (lane 1 in Fig. 4C). These bands migrated at 64 kDa,
75 kDa and 87 kDa, suggesting poly-sumoylation or mono-sumoyla-
tion at multiple sites. As expected, double substitution of K256 and
K345 with arginine in LRBP was able to completely abrogate the
sumoylation (lane 4 in Fig. 4C). However, LRBP–K256R and LRBP–
K345R single mutants showed almost the same sumoylation patterns
as that of wild type LRBP (lanes 2 and 3 in Fig. 4C). This suggests that a
single lysine residue with attachment of poly-SUMOmolecules, either
at position 256 or at position 345, is sufﬁcient for the sumoylation of
LRBP. When sumoylation assays were conducted in the presence of
SUMO1, no sumoylated LRBP could be detected (data not shown).
These results suggest that the sumoylation of LRBP occurs by the
attachment of SUMO2/3, but not SUMO1. On the basis of these results,
we conclude that LRBP is a novel target of sumoylation at the
consensus sites—K256 and K345 by the attachment of SUMO2/3.
4. Discussion
In eukaryotes, highly regulated mRNAs are controlled not only by
the rate of transcription, but also by the rate of degradation [24]. There
are a number of examples where the rate of degradation is controlled
by the binding of proteins to speciﬁc sequences or structures present
in the cognate mRNAs [25–27]. Studies from our laboratory have
shown that ligand-induced down-regulation of LHR mRNA in theovary is mediated by its binding to a cytosolic protein LRBP. This
protein recognizes an 18 mer sequence in the coding region of LHR
mRNA and causes a signiﬁcant decrease in LHRmRNA half life [6]. This
mRNA destabilizing factor was also found to suppress LHR mRNA
translation, by forming an untranslatable mRNP complex [10,13].
While the polysome bound actively translated mRNAs are
distributed throughout the cytosol, the translationally inactive
mRNAs often accumulate in speciﬁc cytosolic foci referred to as P
bodies [28]. The complete protein composition of P bodies is not yet
determined, but a conserved core of proteins functioning in
translation repression and mRNA degradation has been identiﬁed in
P bodies [12]. These proteins include, but are not limited to, the
decapping enzyme Dcp1p/Dcp2p, the activators of decapping Dhh1p/
RCK/p54, Pat1p, the Lsm1p-7p complex, and the exonuclease, Xm1p.
Together, they form the general mRNA repression/decay machinery
that holds or destroys the translationally inactive mRNAs [12].
We hypothesize that during hormone-induced down-regulation,
LHRmRNA transcripts are boundbyLRBP, dissociate fromthe translation
machinery, followed by recruitment to the repression/decaymachinery.
For a better understanding of howLRBP leads to LHRmRNAdegradation,
we performed a yeast two-hybrid screen and examined potential LRBP
interacting proteins. Of all the interacting proteins identiﬁed, RP S20 and
UBCE2i are of particular interest with respect to mRNA degradation.
These two proteins might participate in LHR mRNA degradation by
translocating the untranslated LHR mRNP complex to the decay
pathway. The interaction between LRBP and RP S20, a highly conserved
13 kDa ribosomal protein that belongs to the40S ribosomal subunit [29],
could impair the proper translation initiation of LHRmRNA. It is possible
that when RP S20 is recruited by the cap-binding protein complex, the
associated LRBP prohibits translation initiation by interfering with the
cap-binding protein complex. eIF4E is most likely to be affected by this
interference, since it is a well known target for regulation by various 4E-
bindingproteins [30]. Anotherpossibility is that LRBP–RPS20 interaction
might cause an abnormal conformational change in the 40S ribosomal
subunit, making it unable to be recruited to the 5′UTR of LHRmRNA and
thus prohibiting translation. In either case, an untranslatable mRNP
complex is formed and dissociated from the translation machinery.
The other LRBP interacting protein, ubiquitin conjugating enzyme
E2i (UBCE2i) is a human homolog of yeast UBC9. It is highly conserved—
its sequence being 100% identical with mouse UBC9 and 56% identical
with yeast UBC9. As its name suggests, the protein was originally
thought to be a conjugating enzyme for ubiquitination [18], but is now
recognized to be responsible for a recently identiﬁed type of post-
translational modiﬁcation, sumoylation [31,32]. It should be noted that
UBCE2i is speciﬁc for SUMO, small ubiquitin relatedmodiﬁer, and is not
related to the ubiquitin–proteasome degradation pathway.
Considering that the majority of UBCE2i interacting proteins are
sumoylated, we analyzed the LRBP sequence using SUMOplot™
Analysis software, which predicted two putative sumoylation sites
on the C-terminal domain—Lys 256 and Lys 345. By performing in
vitro sumoylation assays, we consistently obtained three bands of
molecular weight higher than LRBP (lane 1 in Fig. 4C). Furthermore,
substitution of K256/K345 with arginines fully eliminated these
bands (lane 4 in Fig. 4C). Based on these results, we conclude that
LRBP undergoes sumoylation at K256 and/or K345. Appearance of
three bands indicates that multiple SUMOs are attached to the same
LRBP molecule simultaneously. To determine whether these SUMOs
are attached at K256 or K345, we substituted each single lysine with
arginine and subjected the LRBP single mutants to sumoylation
assays. Surprisingly, both K256R and K345R gave similar sumoylation
patterns as the wild type LRBP (lanes 1, 2, and 3 in Fig. 4C). It is likely
that in wild type LRBP, poly-SUMO molecules attach to a single
sumoylation site (K256 or K345), and use the other site as a reserve
site. It is yet unclear whether poly-sumoylation of one site over the
other has any functional consequences. We also observed that the
LRBP is sumoylated by SUMO2/3, but not by SUMO1.
Fig. 4. Identiﬁcation of the sumoylation sites on LRBP. (A) Sequence alignment of C-terminal domains of rat and human LRBP (aa 225–373). The secondary structural elements are
labeled in the ﬁgure, and the sumoylation sites, predicted by SUMOplot™ software, are highlighted in red. (B) 293T cells were transiently transfected to express LRBPwild type (WT),
K256 mutant (K256R), K345 mutant (K345R), or double mutant (K256R/K345R). 10 µg of cell S-100 fraction from each transfection was subjected to SDS-PAGE and immunoblotted
with anti-LRBP polyclonal antibody. (C) 50 µg of cell S-100 fraction from each transfection was used for in vitro sumoylation assay, in the presence of Mg2+ and ATP, as described in
Section 2. The reaction mixtures were separated by 4–15% gradient gel and immunoblotted with anti-SUMO2/3 antibody. (D) A ribbon diagram (generated by Pymol 1.0 software)
showing N- and C-domains of rat LRBP, based on its crystal structure at the resolution of 2.4 A. The sumoylation sites (in green) are on α-8 and β-13 (in purple) respectively.
596 L. Wang et al. / Biochimica et Biophysica Acta 1803 (2010) 591–597Sumoylation was thought of as primarily a nuclear phenomenon,
due to the large number of substrates identiﬁed in the nucleus.
Nonetheless, an expanding number of cytoplasmic proteins have been
reported to exist in sumoylated form, including septins, insulin
dependent glucose transporter GLUT1/4, IKB, etc. [33]. Irrespective of
its localization, either in the nucleus or in the cytoplasm, sumoylation
mainly affects target protein function by altering its subcellular
localization or by antagonizing other modiﬁcations. It has already
been reported that many mRNA binding proteins, such as hnRNP C
[34], hnRNPM and SART1 [35] undergo sumoylation, which facilitates
their nucleocytoplasmic transport. Sumoylation also has been shown
to direct cytosolic transport ofmRNA binding protein La in the sensoryaxons [36]. Thus, we propose that the subcellular localization of
sumoylated LRBP may favor its access to the mRNA decay machinery
in P bodies. It is interesting to note that another mRNA destabilizer
AUF1, which binds speciﬁcally to AU-rich elements of cytokine or
inﬂammatory mediator mRNAs, has been reported to interact with
the component of translation machinery—eIF4G [37] and UBCE2i
[22,38]. It is possible that a common mechanism may exist for AUF1
and LRBP to switch their target mRNAs from translation machinery to
mRNA decay machinery.
In summary, our study for the ﬁrst time has shown that LRBP
interacts with RP S20, a component of the translation apparatus, and
UBCE2i, whichmakes LRBP a novel member of the sumoylated protein
597L. Wang et al. / Biochimica et Biophysica Acta 1803 (2010) 591–597family. These ﬁndings support the hypothesis that LRBP forms an
untranslatable mRNP complex with LHR mRNA and that the
untranslatable mRNP complex becomes associated with the general
repression/decay machinery at speciﬁc cytoplasmic foci. Based on
present in vitro data, we speculate that sumoylation of LRBP might
assist in the targeting of LHR mRNA to the decay machinery. Further
studies are needed to support the functional role of sumoylation of
LRBP in LHR mRNA decay.
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